Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs
Abstract
Aim of investigation. To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.
Material and methods. For the first time in the large group of patients (2934) significant prevalence of serological markers of hepatitis B and C viruses among patients of versatile clinic was demonstrated.
Results. According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. The potential of application of liver graft from the donor with serological profile anti-HCV/anti-HBcor IgG (at absence of other contraindications) is proved for certain groups of recipients. Arguments for revision of criteria for selection of donor of organs were presented for prophylaxis of de novo hepatitis B at the recipient (so-called de novo graft infection – HBsAg appearance at the recipient at absence of viral infection markers before operation).
About the Authors
Ye. N. GermanRussian Federation
M. V. Mayevskaya
Russian Federation
O. I. Andreytseva
Russian Federation
V. T. Ivashkin
Russian Federation
A. V. Chzhao
Russian Federation
A. G. Serova
Russian Federation
G. V. Mikhaylovskaya
Russian Federation
I. Yu. Pirogova
Russian Federation
References
1. Абдурахманов Д.Т. Латентная HBV-инфекция в патогенезе хронических заболеваний печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2002. – Т. 12, № 6. – С. 31–37.
2. Андрейцева О.И. Возможности ортотопической трансплантации печени при лечении больных с терминальными поражениями печени // Consilium Medicum. – 2004. – Т. 6, № 6. – С. 25–27.
3. Галимова С.Ф., Маевская М.В., Ивашкин В.Т. Современные подходы к лечению больных хроническим гепатитом В // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 3. – С. 14–16.
4. Ермолов Е.С., Чжао А.В., Гуляев В.А. и др. Возможности использования инфицированных трупных доноров для выполнения трансплантации печени // Хирургия. – 2006. – № 3. – С. 72.
5. Ивашкин В.Т., Герман Е.Н., Маевская М.В. Скрытая инфекция вирусом гепатита В // Рос. журн. гастроэнтерол. гепатол. колопроктол.. – 2008. – Т. 18, № 2. – С. 4–7.
6. Ивашкин В.Т., Морозова М.А., Маевская М.В. и др. Факторы риска развития гепатоцеллюлярной карциномы // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 1. – С. 4–16.
7. Подымова С.Д. Болезни печени: Руководство для врачей. – 4-е изд., перераб. и доп. – М.: Медицина, 2005. – С. 23.
8. Boonstra A. et al. Immunology of hepatitis B and hepatitis C virus infections // Сlin. Gastroenterol. Best Pract. Res. – 2008. – Vol. 22, N 6. – P. 1049–1061.
9. Brechot C., Hadchouel M., Scotto J. et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases // Proc. Nat. Acad. Sci. USA. – 1981. – Vol. 78. – P. 3906–3910.
10. Brechot C., Thiers V., Kremsdorf D. et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? // Hepatology (Baltimore MD). – 2001. – Vol. 34. – P. 194–203.
11. Cacciola I., Pollicino T., Squadrito G. et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease // N. Engl. J. Med. – 1999. – Vol. 341. – P. 22–26.
12. Chemin I., Trepo C. Clinical impact of occult HBV infections // J. Clin. Virol. – 2005. – Vol. 34. – P. 515–521.
13. Chen S.Y., Kao C.F., Chen C.M. et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein // J. Biol. Chem. – 2003. – Vol. 278. – P. 591–607.
14. Chevrier M.C., St-Louis M., Perreault J. et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay // Transfusion. – 2007. – Vol. 47, N 10. – P. 1794–1802.
15. Fukuda R., Ishimura M., Kushiyama Y. et al. Hepatitis B virus with X gene mutations is associated with the majority of serologically “silent” non-b non-c chronic hepatitis // Microbiol. Immunol. – 1996. – Vol. 40. – P. 481–488.
16. Hu K.Q. Occult hepatitis B virus infection and its clinical implications // J. Viral. Hepat. – 2002. – Vol. 9. – P. 243–257.
17. Koike K., Kobayashi M., Gondo M. et al. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients // J. Med. Virol. – 1998. – Vol. 54. – P. 249–255.
18. Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses // J. Cell. Mol. Med. – 2002. – Vol. 6. – P. 113–143.
19. Larghi A., Leffler D., Frucht H. et al. Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma // J. Clin. Gastroenterol. – 2003. – Vol. 36. – P. 276–280.
20. Pollicino T., Squadrito G., Cerenzia G. et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection // Gastroenterology. – 2004. – Vol. 126. – P. 102–110.
21. Raimondo G. Occult hepatitis B virus infection // J. Hepatol. – 2007. – Vol. 46. – P. 160–170.
22. Raimondo G., Balsano C., Craxi A. et al. Occult hepatitis B virus infection // Dig. Liver Dis. – 2000. – Vol. 32. – P. 822–826.
23. Sagnelli E., Pasquale G., Coppola N. et al. Liver histology in patients with HBsAg negative anti-HBcor and anti-HCV positive chronic hepatitis // J. Med. Virol. – 2005. – Vol. 75, N 2. – P. 222.
24. Saito H., Masuda T., Tada S. et al. Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease // Keio J. Med. – 2009. – Vol. 58, N 3. – P. 161–175.
25. Schuttler C.G. Fiedler N., Schmidt K. et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein // J. Hepatol. – 2002. – Vol. 37. – P. 855–862.
26. Shih C.M., Lo S.J., Miyamura T. et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells // J. Virol. – 1993. – Vol. 67. – P. 5823–5832.
27. Torbenson M., Thomas D.L. Occult hepatitis B // Lancet Infect. Dis. – 2002. – Vol. 2. – P. 479–486.
28. Uchida T., Kaneita Y., Gotoh K. et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection // J. Med. Virol. – 1997. – Vol. 52. – P. 399–405.
29. Villa E., Grottola A., Buttafoco P. et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B // Dig. Dis. Sci. – 1995. – Vol. 40. – P. 8–13.
Review
For citations:
German Ye.N., Mayevskaya M.V., Andreytseva O.I., Ivashkin V.T., Chzhao A.V., Serova A.G., Mikhaylovskaya G.V., Pirogova I.Yu. Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(2):14-21. (In Russ.)
Views:
68
Email this article 
